Suppression and/or cytotoxicity are believed to play an important role in the defense against Epstein-Barr virus (EBV) infection. To analyze the role of suppressor T cells in relation to EBV, we sought to clone and study these T cells. Analysis of 152 T cell clones derived from the peripheral blood of two patients with acute EBV-in4uced infectious mononucleosis (IM) yielded 11 highly suppressive clones that had no cytotoxic activity for the natural killer sensitive K562 cell line, an autologous EBV-infected cell line, or an allogeneic EBV-infected B cell line. Four of six suppressor T cell clones also profoundly inhibited EBVinduced immunoglobulin production, and five of five clones delayed the outgrowth of immortalized cells. These results indicate that during acute IM, suppressor T cells capable of inhibiting B cell activation in the absence of cytotoxicity can be identified, and may play a key role in the control of EBV infection.
Introduction
Epstein-Barr virus (EBV)1 is an ubiquitous herpes virus that has a unique relationship with the immune system. In vitro EBV infects B cells in preference to all other blood cells (1) , and as a consequence of infection these cells proliferate, differentiate into Ig-secreting cells, and eventually become immortalized (2) (3) (4) . In vivo primary infection by EBV is the most common cause of infectious mononucleosis (IM) (5) . Patients with IM have been shown to have a high number of EBV-infected B cells in their peripheral blood that are capable of continuous growth in vitro (6, 7) . Yet patients with this illness very rarely develop monoclonal or polyclonal neoplasms composed of EBV-infected cells. This has been attributed to the vigorous host immune response, consisting ofactivated suppressor (8-1 1) and/or cytotoxic T cells (12) (13) (14) (15) (16) (17) , that develops during the course of the disease. Patients with a congenital disorder of this immune response, referred to as the X-linked lymphoproliferative syndrome, experience fatal episodes of infectious mononucleosis (18, 19) .
After primary infection with EI3V, normal individuals have a small but detectable number of circulating B cells latently infected with EBV that are capable of immortal growth when cultured in vitro (6, 7, 20) . Control ofthese latently infected B cells is also attributed to cytotoxic and/or suppressor T cells that have been described in normal EBV-seropositive individuals (21-24). The importance ofthese immune T cells is demonstrated by the appearance of EBV-induced B cell neoplasms in patients with acquired immunodeficiency syndrome (25) and in those treated with immunosuppressive drugs, such as cyclosporin A (26), or with an anti-T cell monoclonal antibody (27) .
Much information has been accumulated to demonstrate a role for regulatory T cells in the defense against EBV infection (28, 29) . However, unlike T cell responses to a variety ofantigens that have been analyzed in great detail and are relatively well understood (30), very little is known at present about T cell recognition and regulation ofEBV-infected B cells. A preliminary question to be addressed is the relationship among the T cell regulatory mechanisms reported to contribute to the control of EBV-infected B cells, including suppression and specific and nonspecific killing. In this study we have asked whether suppres- sion is an independent mechanism of immune defense to EBV, or whether the apparent suppression is really due to cytotoxic cells killing the B cells and thus preventing Ig production. To address this question, we attempted to isolate and expand suppressor T cell clones from individuals with EBV infection. Although we could not obtain suppressor T cell clones from normal EBV-seropositive individuals, we readily obtained suppressor T cell clones from patients with acute EBV-induced infectious mononucleosis. These results demonstrate that suppression is a distinct defense mechanism against EBV-infected B cells.
Methods
Patients. Patients with EBV-induced IM fulfilling the diagnostic criteria previously reported (9) were referred to the National Institutes ofHealth from Georgetown University Health Center. Blood was obtained in preservative-free heparin from these IM patients and from normal EBVseropositive donors. Antibody titers to EBV-related antigens were determined by Dr. W. Henle, as previously described (31) . Separation of mononuclear cells and enrichment of T and B cell subsets by rosetting with 2-aminoethylisothiouronium bromide-treated sheep red blood cells were performed as previously described (9 Establishment ofB cell lines. EBV-infected B cell lines were established from patients and normals by incubating B cells at a concentration of 500,000 cells/ml in 10-ml RPMI 1640 medium supplemented with 2 mM glutamine, 5 jig/ml gentamycin, and 10% heat-inactivated fetal calf serum (FCS) with 10% vol/vol EBV (filtered supernatant of the B95-8 line with at least 106 transforming U/ml) in 25-cm2 flasks (Coming Glass Works, Coming, NY).
Lymphocyte cultures and assay for suppression ofIg production. T cell suppression of pokeweed mitogen (PWM)-induced At the end of culture the number of Ig-secreting cells was assayed with a modified reverse-hemolytic plaque assay, as described (33 Assayfor interferon. Interferon activity was quantified by a cytopathic effect inhibition assay, as previously described (35 
Results
Three normal EBV-seropositive individuals were selected for this study because their peripheral blood T cells consistently demonstrated high levels of characteristic "late acting" suppressor activity for autologous EBV-infected B cells in vitro (24) . T cell cloning of peripheral blood T cells from these individuals was performed in IL-2-containing medium by limiting dilution techniques with a feeder layer of 20,000 irradiated (4,000 rad) autologous or allogeneic mononuclear cells. In these three normals, the frequency of T cell precursors capable of long-term growth in IL-2-containing medium ranged between 1:9 ( cell line. Of these 167 clones, 156 suppressed by <30% Ig production by allogeneic PWM-activated mononuclear cells (ratio, 1:1) or by autologous EBV-activated B cells (ratio, 2:1). In addition, each of these 156 clones had no significant cytotoxic activity (<20% at 80:1 effector-target ratio) when assayed on the autologous and an allogeneic EBV-infected B cell line. This failure to observe cytotoxic activity was not due to the target B cell line's inability to be lysed, because in each experiment it could be lysed by an alloreactive T cell line. 11 ofthe 167 clones did manifest some inhibitory activity of B cell function (Table  T) . As can be seen, each of these 11 clones suppressed normal PWM-induced Ig production and killed the K562 cell line by >30%. Thus, T cell suppression of Ig production was in each case associated with "natural killer" activity. Only 1 of the 11 clones suppressed EBV-induced Ig production by autologous B cells by >30%, and this inhibitory activity was associated with >30% cytotoxic activity for the autologous and an allogeneic EBV-induced B cell line. Thus, by this technique we were unable to isolate T cell clones from normal peripheral blood that would suppress EBV-induced Ig production in the absence ofcytotoxic function.
In contrast to EBV-seropositive normals, patients with acute EBV-induced IM have high levels of functionally activated suppressor T cells circulating in their peripheral blood that are capable of profoundly suppressing both PWM and EBV-activated cultures in vitro (8-11). We therefore turned to these patients in an attempt to obtain suppressor T cell clones.
Peripheral blood T cells were purified from two patients with serologically confirmed EBV-induced acute IM. Cloning was performed in limiting dilution cultures of purified peripheral blood T cells in 20% IL-2-conditioned medium with a feeder layer of irradiated allogeneic mononuclear cells (20, of one of these suppressor clones is shown in Table III . As few as 12,500 T cells of this clone suppressed the plaque-forming response of 125,000 normal mononuclear cells to PWM by >70%. The coculture of a control T cell clone with no apparent function yields no suppression, showing that suppression in these assays is not due to a nonspecific effect. After establishing the suppressor nature of these 11 clones, we examined each for its ability to kill the K562 cell line, an autologous EBV-infected B cell line, and an allogeneic EBVinfected B cell line (Table II) . Testing for cytotoxicity was initially performed 7-9 wk after cloning. In sharp contrast to the clones from normal EBV-immune individuals, none of these 11 suppressor T cell clones from the IM patients was capable of killing any ofthe targets tested. This lack ofcytotoxicity was a consistent Fig. 2 . Normal mononuclear cells used as the positive control demonstrated good killing of the K562 targets, whereas the three suppressor clones examined in this experiment had no cytotoxic activity at effector-target ratios up to 80:1 or 100:1 (Fig. 2 A) . Similarly, the three clones shown did not kill the autologous EBV-infected targets, while the positive control alloreactive cytotoxic T cell line killed the EBVinfected targets well (Fig. 2 B) . This failure to kill could reflect the absence of specific antigenic stimulation during a prolonged (7- tion. At the time of this testing the T cell clones had been in culture for -15 wk. Four of these six T cell clones suppressed the plaque-forming cell response of autologous EBV-activated B cells by >60% (Table II) . The other two clones that also markedly suppressed PWM-induced Ig failed to suppress EBV-induced Ig production at this cell ratio. We next asked if these T cell clones from patient H.C. that were capable of suppressing without killing could regulate another assay of EBV activation, immortalization or outgrowth of autologous B cells freshly infected with EBV. In these experiments, 5,000 H.C. B cells were infected with EBV and cultured alone or with 100,000 H.C. T cells, whose activity was to be tested. The T cells used included H.C. T cells obtained after recovery from IM, one H.C. T cell clone that had no apparent function, and five ofthe H.C. T cell clones demonstrating >70% suppressor activity. One of these clones (92.56) stopped growing after 16 wk and could not be tested; the remaining clones were tested 17 wk after cloning. By 3 wk after initiation of culture, all wells containing EBV-infected B cells alone showed evidence of outgrowth (Table IV) . Outgrowth from wells containing EBVactivated B cells and 100,000 T cells from each of the five suppressor clones was clearly inhibited at 3 wk. This outgrowth inhibition was not due to nonspecific cell crowding effects since no inhibition of B cell outgrowth was seen in the presence of the nonfunctional H.C. clone 92.75. After 4 wk in culture, however, most wells containing the suppressor clones did show evidence of outgrowth. Thus, the suppressor clones significantly delayed, but did not prevent, the outgrowth of freshly EBVinfected B cells. As expected, the control wells containing T cells from the patient during convalescence completely inhibited the outgrowth of autologous EBV-infected B cells (38) .
To explore the mechanism ofsuppression by IM T cell clones, we tested cell-free supernatants for their ability to inhibit Ig production. Five suppressor T cell clones and a control nonsuppressor T cell clone that had been in continuous culture for 8-12 wk were incubated in 10% FCS medium at a cell density of 1 X 106 cells/ml for 1, 3, and 5 d, when supernatants were removed for testing. Unlike the T cells from the inhibitory clones, which markedly suppressed Ig production by normal cocultured mononuclear cells, their supernatants had little or no suppressive effect (Table V) . When tested for the presence of interferon activity on WISH cells, each of the 5-d culture supernatants of the suppressor T cell clones contained small amounts of interferon (16-40 U/ml). This was identified as gamma interferon, since these supernatants had no protective effect (<5 U/ml) when tested on MDBK cells. In contrast, the supernatant of a control nonsuppressor clone was negative for interferon. In further analysis of the mechanism for T cell suppression, we tested for the possibility that a relative deficiency of IL-2, removed by the IL-2-dependent suppressor T cell clones, could account for inhibition of Ig production by normal cocultured cells. To this end, recombinant human IL-2 (gift of Cetus Corp., Berkeley, CA) was added to normal mononuclear cells cultured in the presence of PWM either alone or with T cells from two suppressor T cell clones (92.06 and 92.50). In data not shown, recombinant IL-2 at final concentrations ranging between 10 and 1,000 U/ml failed to reverse inhibition by the suppressor clones.
Suppressor Clones in Infectious Mononucleosis 11 Separate testing showed that the recombinant IL-2 allowed maximal T cell proliferation at a final concentration of 50 U/ml. Cell surface antigen phenotypes of the 11 suppressor T cell clones from IM patients are shown in Table IT . All clones were T3 and TI 1 positive. Three T cell clones from patient C.S. were T8 positive, and two were T4 positive. Five of the T cell clones from patient H.C. were T4 positive, and one was T8 positive.
Discussion
One of the clearest examples of balance between the immune system and disease is represented by EBV infection. EBV is an ubiquitous virus that infects most ofthe world's adult population (39) . Primary infection with this virus is either asymptomatic or results in the usually benign disease ofacute infectious mononucleosis (5). Recovery is followed by a long-lasting and generally asymptomatic latent state of infection (7, 39, 40) . Suppression of the normal immune response by agents such as cyclosporin A (26) or an anti-T cell monoclonal antibody (27) and suppression in association with congenital or acquired immunodeficiencies (18, 19, 25) have, however, resulted in the emergence of EBV-induced malignancies.
This balance between the immune response and EBV infection is closely paralleled by in vitro studies that offer a unique opportunity for investigation. In vitro studies have shown that EBV is capable of activating B cells to proliferate, differentiate into Ig-producing cells, and eventually transform into immortal B cell lines (2) (3) (4) . EBV-related regulatory T cells can prevent these effects ofEBV activation in vitro (26, 27) . T concentrations failed to reverse T cell suppression, gamma interferon was present in the supernatants of all suppressor T cell clones examined, though at low levels ranging between 16 and 40 U/ml. A control clone produced no interferon. It is possible that gamma interferon secretion is the mechanism ofinhibition by IM suppressor T cells, because recombinant gamma interferon at comparable concentrations (10-50 U/ml) has been shown to profoundly suppress EBV-induced Ig production (43) . This possibility, however, needs further analysis, since cell-free supernatants of the suppressor T cell clones containing the gamma interferon failed to show significant suppression.
The growth of functional suppressor T cell clones from IM patients is unlikely to result solely from allostimulation from the feeder cells used during the initial days of culture, because we were unable to obtain similar clones from normal individuals using identical methods. In addition, it is known that IM T cells respond poorly to allostimulation when compared with normal T cells (44, 45) , and that the frequency of alloreactive T cell clones in normal individuals is only from 1:200 to 1:600 (46).
The cell surface phenotyping of these T cell clones was also somewhat surprising. Acute IM is characterized by a T cell lymphocytosis, and a major component of this elevated lymphocyte number is composed of T cells bearing the T8 (suppressor/cytotoxic) surface antigen (47) . It was therefore surprising that 7 of the 11 T cell clones from the IM patients were T4 positive/ T8 negative. Since these were T4-positive cells, we must consider whether they were inducers of suppression rather than suppressor-effector cells. These clones were, however, able to suppress EBV-induced Ig production by T cell-depleted population of B cells, strongly suggesting that the cells do indeed have suppressor effector activity.
Thus suppressor T cell clones that are capable of blocking both PWM-and EBV-induced Ig production as well as delaying the outgrowth of EBV-infected B cells without detectable cytotoxicity can be grown from the peripheral blood ofIM patients. Using identical culture techniques, similar clones could not be identified in the blood of any three normal EBV-seropositive individuals. In these cases all the inhibitory T cell clones were nonspecifically cytotoxic for at least some of the target cell lines used, and may thus represent natural or lymphokine-activated killer cells (48) . This failure is likely due to a relatively low frequency of EBV-related regulatory cells in normal EBV-immune blood, and it is possible that different approaches of isolating these cells will be successful.
These studies establish a distinction between suppression and cytotoxicity in T cells derived from patients with acute EBVinduced IM. These regulatory cells may play an important role in the control of primary EBV infection by inhibiting without killing EBV-infected B cells. Suppression, therefore, provides a distinct mechanism for the control of EBV infection.
